Rheumatology E-learning. University of Szeged Department of Rheumatology and Immunology
|
|
- Myra Warner
- 5 years ago
- Views:
Transcription
1 Rheumatology E-learning University of Szeged Department of Rheumatology and Immunology
2 Rheumatoid arthritis Prevalence: 1:200 the most common chronic polyarthritis worldwide Female:male: 3:1 Peak incidence: years Clinical characteristics: Symmetric, chronic, inflammation, involving both the small- and large joints Erosive arthritis leads to progressive articular damage, functional deterioration and disability The characteristic involvement of the fingers and wrists Systemic signs premature death without appropriate treatment
3 Rheumatoid arthritis cartilage and bone destruction Normal synovial layer: a thin membrane of loosely associated fibroblast- and macrophagelike mesenchymal cells lining the articular capsule Rheumatoid synovium: an agressively proliferating inflammatory tissue with several cell types and a huge overproduction of proinflammatory cytokines and tissuedegrading enzymes (=pannus)
4 Early rheumatoid arthritis Swelling of PIP (left) and MCP and PIP (below) joint lines
5 The hand in rheumatoid arthritis Early RA: Swelling and tenderness of the wrist, MCP and PIP lines but the DIP line is very rarely involved! Morning stiffness > 1 hour Fist formation is not complete Grasping force is decreased (unscrewing a cap, use of a hand, writing, etc.)
6 Longstanding RA Ulnar deviation of fingers Flexion contracture in the MCP joints Z-deformity ( hitch-hiker ) in the thumb Rheumatoid nodules
7 Chronic RA
8 The hand in rheumatoid arthritis Long-standing RA: Wrist movements are restricted. The ulnar head is hypermobile ( piano key sign ) or subluxed. Median nerve compression carpal tunnel syndrome I. MCP and PIP subluxation hitch-hiker deformity II-V. MCP: flexion contracture, ulnar deviation Interosseus muscle atrophy Boutonniére and swan neck deformity Ankylosis, subluxation, tendon rupture
9 Characteristic deformities in RA Boutonniére deformity Swan neck deformity
10 Characteristic deformities in RA Ulnar deviation + Flexion contracture in MCP
11 Radiographic progression of damage in rheumatoid arthritis Linear osteoporosis around MCP and PIP joints early stage Erosions (arrow) bone defects next to the involved joints Joint space narrowing Deformities, subluxations, ankylosis final stage
12 Rheumatoid arthritis - foot Depressed transverse arch Hallux valgus Digitus malleus (hammer toe)
13 Atlanto-axial instability The intervertebrate joint between the 1st and 2nd vertebrae (atlas and axis) becomes unstable due to a degeneration of the dens and the loosening of the ligaments The spinal cord or the medulla oblongata are compressed during extreme head movements May be fatal (cardio-respiratiory centre laesion, rupture of the spinal cord Caution: head movements, gymnastics, intubation, dental procedures
14 Rheumatoid arthritis cervical spine MRI
15 Rheumatoid arthritis extra-articular symptoms Rheumatoid nodule Pericarditis Pulmonary fibrosis Rheumatoid vasculitis Secondary Sjögren s syndrome, episcleritis, scleritis, scleromalacia perforans Nervous system involvement compression neuropathy (tunnel syndromes) polyneuropathy / multiple mononeuritis craniocervical instability Secondary amyloidosis Accelerated atherosclerosis Osteoporosis Lymphoma
16 Rheumatoid nodule Subcutaneous nodules on the extensor surfaces of the limbs Their presence is usually associated with a more severe disease course. Rarely they may be found in the heart and lung too.
17 Rheumatoid vasculitis Requires high dose intravenous corticosteroid and cyclophosphamide treatment
18 Episcleritis, scleritis, scleromalacia perforans
19 Arthritis and atherosclerosis Lot of common mediators - CRP, autoantibodies, lipids, adhaesion molecules
20 CV event-free probability Untreated RA carries the same cardiovascular risk as type-2 diabetes mellitus Control T2DM RA years
21 CVD is the most prevalent extra-articular and systemic manifestation in RA Prevalence of ExRA and SysM by year Year Hochberg MC et al. Current Medical Research and Opinion 2008; 24(2):
22 Rheumatoid arthritis pathogenesis I. Genetics Polygenic (more than 50 risk loci identified -Most of the risk is carried by HLA-DR4 alleles, that share a common antigen-binding motif ( shared epitope ) Environmental factors -Smoking -High fat diet -Excessive caffeine -Alcohol protective (in moderate amounts)
23 The role of citrullinated peptides in RA Arginine Citrulline Post-translational modification by PAD (peptidil-arginin deiminase) A biochemical pathway universally present in inflammatory processes Result: citrullinated vimentin, fibronectin, EBNA, fibrin If particular, special citrullinated epitopes are formed these may behave as autoantigens Shared epitope (serologically: HLA-DR4, by genotyping: HLA DRB1*0401, 0404, 0408 ) short, structurally similar sequences located on the 3rd hypervariable region of the HLA-DRB1 chain, which bind similar peptide sequences on various proteins and present them as (auto)antigens
24 Histograms of odds ratios for developing anti-ccp-positive (A) and anti-ccp-negative (B) rheumatoid arthritis (RA) for different combinations of absence or presence of single or double HLA- DRB1 shared epitope (SE) alleles, and smoking Risk of development of RA: smoking: 3x, shared-epitope (double gene copies): 5x, smoking + shared-epitope: 25x synergistic geneticenvironmental interaction Kallberg et al Am J Hum Genet 2007;80:867 75)
25 Periodontitis and RA are closely associated Source:
26 Association between periodontal disease and RA Hyppocrates: pulling teeth may cure arthritis Periodontal disease is more prevalent among smokers Periodontitis is more common in RA patients Rutger Persson G, J Oral Microbiol 2012, Bertehlot JM, Joint Bone Spine 2010 Smoking is a shared risk factor the association is present also in non-smokers Potikuri D, Ann Rheum Dis 2012
27 Association between periodontal disease and RA The severity of periodontal disease correlates with disease activity of RA Kobayashi T, J Periodontol 2010 Antibiotic or dental treatment of periodontitis reduces RA disease activity Ortiz P, J Periodontol 2009 Severe periodontal disease diminishes the therapeutic efficacy of anti-tnf therapy of RA Savioli C, J Clin Rheum 2012 Anti-TNF therapy may improve periodontitis Mayer Y, J Periodontol 2009 Alveolar bone loss is parallel with juxtaarticular bony erosions of RA patients 2006 Marotte H, Ann Rheum Dis
28 Porphyromonas gingivalis a major player in the switch from periodontitis to RA? Anaerobic rod-shaped bacterium Rarely present in periodontally healthy individuals Its colonization in the periodontal sac is necessary for the development of periodontitis Unique among prokaryotes for expressing PAD
29 Summary current concept of RA pathogenesis Smoking: chronic inflammation in periodontal tissues and bronchi pro-immunogenic milieu altered microbiome increased citrullination In HLA-DR4 shared-epitope carriers: citrullinated epitopes generate anticitrullinated peptide antibodies A subsequent further hit : these antibodies become pathogenic and cause arthritis
30 Rheumatoid arthritis pathogenesis what happens in the synovium? Key players potential drug targets
31 Rheumatoid arthritis 2010 ACR-EULAR classification criteria A. Articular involvement 1 large joint large joints small joints small joints 3 >10 joints (at least1 small joint) 5 B. Serology (at least 1 positive is needed) Negative RF and ACPA 0 Low positive RF or ACPA 2 High positive RF or ACPA 3 C. Acute phase response (at least 1 positive is needed) Normal CRP and normal ESR 0 6/10 is required Abnormal CRP or ESR 1 for definite RA D. Duration of symptoms <6 weeks 0 >6 weeks 1
32 Rheumatoid arthritis - progression Irreversible damage (erosions on X- ray) appears as early as 4-6 months Delayed therapy can not eliminate subsequent destruction, it can only slow it down
33 Rheumatoid arthritis principles of therapy Early diagnosis Early recognition (effective therapy has to be initiated not later than 3 months after the first symptoms!) Differential diagnosis must be thorough but rapid Bad prognostic signs Anti-citrullinated peptide antibody-positivity Early erosions on X-ray High number of inflamed joints Early initiation of immunosuppressive treatment T2T = treat to target: goal: complete remission (=no inflamed joint, normal C-reactive protein). If suboptimal therapy: joint damage will continue to progress
34 The concept of early arthritis Joint pain and swelling not due to trauma or infection The involvement of at least 2 articular regions MCP or MTP involvement At least 30 minutes of morning joint stiffness These patients have RA or are at high risk of RA: therefore, after thorough but rapid differentialdiagnosis (exclude infection, malignancy, SLE, etc.), initiation of a DMARD (disease-modifying antirheumatic drug) treatment is indicated, ideally within six weeks
35 Rheumatoid arthritis treatment I. Anti-inflammatory treatment non-steroidal anti-inflammatory drug (NSAID) rarely enough corticosteroid ( ~ 8-24 mg methylprednisolon/day) first 3 months of therapy, then taper off! DMARD (disease-modifying anti-rheumatic drug) slow action, inhibition of progression the induction of long-lasting remission in early arthritis? methotrexate Leflunomide hydroxychloroquin sulfasalazine
36 Rheumatoid arthritis treatment II. Disease-modifying anti-rheumatic drugs (DMARD) Interfere with the basic processes of disease pathogenesis not symptomatic therapies Action takes effect 2-3 months after the initiation Usually administered for many years (even decades) because the disease recurs if the drugs are stopped Immunosuppressives constant awareness for infections Liver, kidney function and blood count has to be checked every 2 months (after initiation: every 2 weeks!) Methotrexate and leflunomide are the two most potent but even these agents can induce remission only in 60-70% of patients If insufficient switch or combine In therapy resistance (disease remains active): biological or other targeted therapies should be started
37 Rheumatoid arthritis treatment III. Targeted therapies: specifically target key players of the pathogenesis (not empirical but hypothesis-driven, evidence-based therapies) Most of them are monoclonal antibodies (biological therapies) More recently, orally available, small molecular targeted therapies have been introduced (e.g. Janus kinase inhibitors)
38 RA biological therapy B-lymphocyte CD20 CD80 CTLA4 CD28 Th0 lymphocyte Plasma cell TNF- IL-1 Anti-TNF:infliximab, adalimumab, etanercept, certolizumab, golimumab IL1-receptor antagonist: anakinra CTLA4Ig (costimulation blocker): abatacept Anti-CD20 (B-lymphocyte depleting): rituximab Anti-IL6-receptor: tocilizumab Activated Th1 lymphocyte IL-6 Synovial cell / macrophage
39
40 Biological therapy in rheumatology RA: anti-tnf, B-cell depletion, IL6-inhibition, costimulation-blocade Ankylosing spondylitis, psoriatic arthritis anti-tnf, anti- IL17 Juvenile idiopathiic arthritis polyarticular form anti-tnf Juvenile idiopathic arthritis systemic form IL6-blocker, IL1-blocker Systemic lupus erythematosus, ANCA-associated vasculitis (dermatomyositis, systemic sclerosis/scleroderma, Sjögren s etc.): B-cell depletion Hereditary autoinflammatory syndromes: IL1-blocker Polymyalgia rheumatica, giant cell arteritis: IL6-blocker
41 Rheumatoid arthritis: biological therapy When to use them? In persistently active polyarthritis despite methotrexate, subsequently combined DMARD (MTX + LEF, MTX + AZA, MTX + cyclosporin ) about 20% of all RA cases Forms of administration: subcutaneous injection (home administration) or iv. infusion (outpatient unit-based administration) Contraindications: active or latent tuberculosis (PPD test, Quantiferon), impaired left ventricular systolic function (EF < 50%), hepatitis B or other chronic infection, recent maligancy First line: anti-tnf, IL6-blocker Addition of methotrexate or leflunomide is recommended (or even mandatory for some biologicals) Inefficacy or adverse effects: switch other anti-tnf or other drug class. Long-standing complete remission: 30-50% Permanent cessation? Personalized biological therapy?
Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationThe Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics
+ The Rheumatoid Hand Deformities & Management Dr. Anirudh Sharma Resident Department of Orthopedics + Why is Rheumatoid Arthritis important? + RA is a very debilitating disease median life expectancy
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationRheumatoid Arthritis. Update in Rheumatoid Arthritis Diagnosis and Therapy. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Update in Rheumatoid Arthritis Diagnosis and Therapy Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid Arthritis Clinic
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAOS 3: Rheumatoid Arthritis
AOS 3: Rheumatoid Arthritis Arthritis (General) = inflamed joint - NOT a single disease: covers >100 types - Involves disability + decreased quality of life o Can also occur in young people (not just the
More informationRheumatology for GP Trainees: Inflammatory Arthritides (RA Including Early Recognition and Pharmacotherapeutics)
Rheumatology for GP Trainees: Inflammatory Arthritides (RA Including Early Recognition and Pharmacotherapeutics) Dr Martin Lee MRCP(Rheum) Rheumatology Consultant and Associate Clinical Lecturer The Freeman
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationwww.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high
More informationSystemic forms of stiffness
Systemic forms of stiffness ANNA LITWIC CONSULTANT RHEUMATOLOGIST SALISBURY DISTRICT HOSPITAL CLINICAL RESEARCH FELLOW MRC LIFECOURSE EPIDEMIOLOGY UNIT Overview Rheumatoid arthritis Know it when you see
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationRheumatoid arthritis
Rheumatoid arthritis LECTURE IN INTERNAL MEDICINE FOR V COURSE STUDENTS M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, N. Makienko V.N. Karazin National University Medical School
More informationRHEUMATOID ARTHRITIS AND ANAESTHESIA - PART 1 ANAESTHESIA TUTORIAL OF THE WEEK 266
RHEUMATOID ARTHRITIS AND ANAESTHESIA - PART 1 ANAESTHESIA TUTORIAL OF THE WEEK 266 6 TH AUGUST 2012 Dr Rashmi Menon Leeds General Infirmary Correspondence to rashmimenon@doctors.org.uk QUESTIONS 1. Regarding
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationEtiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationRequirements in the Development of an Autoimmune Disease Amino Acids in the Shared Epitope
+ T cell MHC/self-peptide MHC/Vβ Induction of + T H 1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and type I diabetes APC Activated autoreactive +
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationRheumatoid Arthritis 2. Inflammatory Diseases. Definition. Imaging Signs
Rheumatoid Arthritis 2 Definition " Epidemiology Affects 2% of the population Peak incidence (diagnosis) in 4th and 5th decades Women affected 3 4 times more often than men Increased familial incidence
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationWhen is it Rheumatoid Arthritis When to Refer
When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis
More informationKelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationRECOMMENDATIONS FOR THE USE OF BIOLOGICAL AGENTS FOR THE TREATMENT OF RHEUMATIC DISEASES*
RECOMMENDATIONS FOR THE USE OF BIOLOGICAL AGENTS FOR THE TREATMENT OF RHEUMATIC DISEASES* * DISCLAIMER These recommendations are written to assist Australian rheumatologists prescribing biological agents
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationRheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Rheumatic Diseases The prevalence of rheumatoid arthritis in most Caucasian populations approaches 1% among adults 18 and over and
More informationRheumatoid Arthritis
Rheumatoid Arthritis Introduction Rheumatoid arthritis is a fairly common joint disease that affects up to 2 million Americans. Rheumatoid arthritis is one of the most debilitating forms of arthritis.
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationEARLY INFLAMMATORY ARTHRITIS. Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital
EARLY INFLAMMATORY ARTHRITIS Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital EIA: Introduction National priority Preventable cause of disability Very common condition High
More informationPATHOGENESIS OF RHEUMATOID ARTHRITIS
PATHOGENESIS OF RHEUMATOID ARTHRITIS Division of Rheumatology Department of Internal Medicine College of Medicine Seoul National University Seoul National University Bundang Hospital Yun Jong Lee Rheumatoid
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationTypes of osteoarthritis
ARTHRITIS Osteoarthritis is a degenerative joint disease is the most common joint disorder. It is a frequent part of aging and is an important cause of physical disability in persons older than 65 years
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationAmino acid sequences in the β chain HLA- DRB*0401 molecules dictate susceptibility to RA Amino Acids in the Shared Epitope
MHC/self-peptide MHC/Vβ TCR Vβx + Vβx T cell Induction of + TH1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and APC type I diabetes TCR Vβx Activated
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 284.9 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationAdult-onset Still s disease a polygenic autoinflammatory disease
Adult-onset Still s disease a polygenic autoinflammatory disease Tom Pettersson, MD, PhD University of Helsinki and Helsinki University Central Hospital IL-1 mediated diseases past present and future Såstaholm
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationBiologic agents in Internal Medicine-2018: Targeted therapies for.
Biologic agents in Internal Medicine-2018: Targeted therapies for. Chronic inflammatory diseases affecting the skin Chronic inflammatory diseases affecting the gut Chronic inflammatory diseases affecting
More informationCase reports CASE 1. A 67-year-old white man had back pain since the age. our clinic several years later with progressive symptoms.
Annals of the Rheumatic Diseases, 1982, 41, 574-578 Late-onset peripheral joint disease in ankylosing spondylitis MARC D. COHEN AND WILLIAM W. GINSBURG From the Division ofrheumatology and Internal Medicine,
More informationRheumatology Primer: What Labs and When
Rheumatology Primer: What Labs and When Irina Konon, MD Department of Internal Medicine Division of Rheumatology Medical College of Wisconsin Disclosures None 1 Objective Discuss principles of laboratory
More informationThe Role of the Physician Assistant in the Management of the RA Patient
For your information Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Private practice, Tustin CA Investigator in clinical trials relevant to this lecture including: anti-tnf for
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationUltrasound in Rheumatology
Arthritis Research UK Primary Care Centre Winner of a Queen s Anniversary Prize For Higher and Further Education 2009 Ultrasound in Rheumatology Alison Hall Consultant MSK Sonographer/Research Fellow Primary
More informationI nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
More informationRheumatoid Arthritis in Asians
NO DISCLOSURES Rheumatoid rthritis in sians Mary C. Nakamura M.D. Professor of Medicine, UCSF Rheumatoid rthritis Rheumatoid rthritis Polyarthritis of synovial lined joints Inflammatory Characteristic
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationA CRP B FBC C LFT D blood culture E uric acid
1 A 39 year old lady with rheumatoid arthritis is admitted to hospital with a hot, swollen and painful right knee. Which is the most important blood test? A CRP B FBC C LFT D blood culture E uric acid
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0043I Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationHigh Impact Rheumatology
High Impact Rheumatology Evaluation and Management of Rheumatoid Arthritis Rheumatoid Arthritis: Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis
More informationClinical Challenges in Arthritis: Care Plans and Interventions That Achieve Results Primary Care Updates Boston, Massachusetts September 19, 2013
Clinical Challenges in Arthritis: Care Plans and Interventions That Achieve Results Primary Care Updates Boston, Massachusetts September 19, 2013 Content Collaborator: Session 1: Clinical Challenges in
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationDifferential Diagnosis And Tests Of Rheumatoid Arthritis And Its Implication For Physiotherapy
Differential Diagnosis And Tests Of Rheumatoid Arthritis And Its Implication For Physiotherapy Onwunzo Chinelo Nkemdilim Physiotherapy Unit, General Hospital Ekwulobia, Ministry of Health, Awka, Anambra
More informationClinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Contents Introduction...3 What is rheumatoid arthritis?...4 Symptoms of rheumatoid arthritis... 5 What causes rheumatoid arthritis?... 10 The role of genes and family
More informationBIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG
BIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG INTRODUCTION JIA is the most common chronic rheumatic inflammatory disease of childhood. If not successfully
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationHistory Taking and the Musculoskeletal Examination
History Taking and the Musculoskeletal Examination Introduction A thorough rheumatologic assessment is performed within the context of a good general evaluation of the patient. The patient should be undressed
More informationCHAPTER 13 SKELETAL SYSTEM
CHAPTER 13 SKELETAL SYSTEM Structure and Function Functions of the skeletal system Provides shape and support Protects internal organs Stores minerals and fat Produces blood cells and platelets Assists
More information